PF-08046054 by Pfizer for Melanoma: Likelihood of Approval

PF-08046054 is under clinical development by Pfizer and currently in Phase I for Melanoma.

Precision oncology therapies account for nearly half of new cancer drug approvals since 1998

Of the 198 new oncology drugs approved by the U.S. Food and Drug Administration (FDA) between 1998 and 2022, approximately 43% were precision oncology therapies,

October 18, 2023

ACIP recommends routine use of mpox vaccine for at-risk adults, opening the door to potential 2024 launch

The CDC’s Advisory Committee on Immunization Practices (ACIP) has voted in favor of routine use of the mpox vaccine Jynneos, opening the door to potential

October 26, 2023

Mydecine Innovations Announces Closing of Prospectus Supplement Financing | Psychedelic Invest

Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly

September 20, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.